| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.01.
| Galena Biopharma Initiates Phase III PRESENT Trial Of NeuVax Ahead of Schedule | | 9 | Zacks |
| 20.01.
| Galena Biopharma (GALE) Initiates NeuVax Phase 3 | | 5 | StreetInsider.com |
| 09.12.
| Galena Biopharma (GALE) Updates on NeuVax w/ Herceptin Phase 2 Design | | 2 | StreetInsider.com |
| 07.12.
| Shares of Galena Biopharma (GALE) Trade up 22% on 5 Year NeuVax Efficacy Data | | 1 | StreetInsider.com |
| 01.12.
| Lead Drug Candidates From Galena Biopharma and Arena Pharmaceuticals Look to Make Big Splash in 2012 / The Bedford Report Provides Equity Research on Galena Biopharma & Arena Pharmaceuticals | | 62 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 12/01/11 -- 2012 is shaping up to be a big year for the biotechnology industry with several drug candidates facing FDA advisory panels. The drug approval rate in the...
Mehr lesen zu:
Lead Drug Candidates From Galena Biopharma and Arena Pharmaceuticals Look to Make Big Splash in 2012 / The Bedford Report Provides Equity Research on Galena Biopharma & Arena Pharmaceuticals | |
| 28.11.
| Shares of Galena Biopharma (GALE) Trade Up on Collaboration With Genentech/Roche & The Henry M. Jackson Foundation | | 4 | StreetInsider.com |
| 18.11.
| Galena Biopharma (GALE) Announces 2 Presentations at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium | | 1 | StreetInsider.com |
| 28.10.
| RXI PHARMACEUTICALS CORP - 10-Q/A, Quarterly Report | | 2 | SEC Filings |
| 20.10.
| Galena Biopharma (RXII) Announces Phase 1/2 Clinical Trial Results of NeuVax were Published in The Journal Cancer this Month | | 1 | StreetInsider.com |
| 29.09.
| FRA: DELETION OF INSTRUMENTS FROM XETRA - 29.09.2011 | | 321 | Xetra Newsboard |
| The following instruments on XETRA do have their last trading day on 29.09.2011 Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 29.09.2011 ISIN Name CA88102D1033 TERRA NOVA ROYALTY...
Mehr lesen zu:
FRA: DELETION OF INSTRUMENTS FROM XETRA - 29.09.2011 | |
| 29.09.
| DIVERSE: AENDERUNG / CHANGE ISIN | | 271 | Xetra Newsboard |
| FUER FOLGENDE INSTRUMENTE WERDEN ISIN, WKN UND KUERZEL GEAENDERT. GUELTIG AB: 30.09.2011. FOR THE FOLLOWING INSTRUMENTS ISIN, WKN AND SHORT CODE WILL CHANGE. VALID FROM SEPTEMBER 30, 2011. Einstellung...
Mehr lesen zu:
DIVERSE: AENDERUNG / CHANGE ISIN | |
| 27.09.
| RXK: AUSSETZUNG/SUSPENSION | | 36 | Xetra Newsboard |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL RXI PHARMACEUTICALS RXK US74978T1097 BAW/UFN
Mehr lesen zu:
RXK: AUSSETZUNG/SUSPENSION | |
| 26.09.
| RXi Pharma (RXII) to Split into Two Public Companies | | 19 | StreetInsider.com |
| 21.09.
| RXi Pharma Licenses New, FBP Targeted Vaccine For Gynecological Cancers | | 44 | AFX News |
| WASHINGTON (dpa-AFX) - RXi Pharmaceuticals Corp. (RXII) said it licensed
worldwide rights to develop and commercialize a Folate Binding Protein-E39, or
FBP, targeted vaccine to prevent recurrence...
Mehr lesen zu:
RXi Pharma Licenses New, FBP Targeted Vaccine For Gynecological Cancers | |
| 21.09.
| RXi Pharma (RXII) Licenses Worldwide FBP Rights from MD Anderson | | 1 | StreetInsider.com |
| 12.09.
| RXi Pharmaceuticals (RXII) Announces Clinical Trial Update on NeuVax, FDA Withdraws Hold | | 1 | StreetInsider.com |
